- Home
- KZIA vs DUO Comparison
KZIA vs DUO Comparison
Compare KZIA & DUO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- DUO
- Stock Information
- Founded
- KZIA 1994
- DUO 2011
- Country
- KZIA Australia
- DUO China
- Employees
- KZIA N/A
- DUO N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- DUO Real Estate
- Sector
- KZIA Health Care
- DUO Finance
- Exchange
- KZIA Nasdaq
- DUO Nasdaq
- Market Cap
- KZIA 12.6M
- DUO 14.6M
- IPO Year
- KZIA 1999
- DUO 2019
- Fundamental
- Price
- KZIA $4.90
- DUO $0.65
- Analyst Decision
- KZIA Strong Buy
- DUO
- Analyst Count
- KZIA 1
- DUO 0
- Target Price
- KZIA $20.00
- DUO N/A
- AVG Volume (30 Days)
- KZIA 148.4K
- DUO 5.8M
- Earning Date
- KZIA 11-19-2024
- DUO 08-30-2024
- Dividend Yield
- KZIA N/A
- DUO N/A
- EPS Growth
- KZIA N/A
- DUO N/A
- EPS
- KZIA N/A
- DUO N/A
- Revenue
- KZIA $382.00
- DUO $37,352,654.00
- Revenue This Year
- KZIA $4,053,954.00
- DUO N/A
- Revenue Next Year
- KZIA N/A
- DUO N/A
- P/E Ratio
- KZIA N/A
- DUO N/A
- Revenue Growth
- KZIA N/A
- DUO 6.61
- 52 Week Low
- KZIA $1.90
- DUO $0.32
- 52 Week High
- KZIA $15.80
- DUO $4.67
- Technical
- Relative Strength Index (RSI)
- KZIA 50.25
- DUO 38.61
- Support Level
- KZIA $5.21
- DUO $0.65
- Resistance Level
- KZIA $6.88
- DUO $0.98
- Average True Range (ATR)
- KZIA 0.76
- DUO 0.15
- MACD
- KZIA -0.11
- DUO -0.05
- Stochastic Oscillator
- KZIA 22.80
- DUO 1.74
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.
About DUO Fangdd Network Group Ltd.
Fangdd Network Group Ltd is an investment holding company. Through its subsidiaries, It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.